134 related articles for article (PubMed ID: 28780998)
21. Risk factors for hospitalized patients with resistant or multidrug-resistant
Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
[TBL] [Abstract][Full Text] [Related]
22. Carbapenem inactivation: a very affordable and highly specific method for phenotypic detection of carbapenemase-producing Pseudomonas aeruginosa isolates compared with other methods.
Akhi MT; Khalili Y; Ghotaslou R; Kafil HS; Yousefi S; Nagili B; Goli HR
J Chemother; 2017 Jun; 29(3):144-149. PubMed ID: 27443547
[TBL] [Abstract][Full Text] [Related]
23. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
Mohanty S; Maurya V; Gaind R; Deb M
J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
[TBL] [Abstract][Full Text] [Related]
25. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.
Pakyz AL; Oinonen M; Polk RE
Antimicrob Agents Chemother; 2009 May; 53(5):1983-6. PubMed ID: 19273670
[TBL] [Abstract][Full Text] [Related]
26. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
27. Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland.
Pobiega M; Maciąg J; Chmielarczyk A; Romaniszyn D; Pomorska-Wesolowska M; Ziolkowski G; Heczko PB; Bulanda M; Wojkowska-Mach J
Diagn Microbiol Infect Dis; 2015 Nov; 83(3):295-7. PubMed ID: 26341705
[TBL] [Abstract][Full Text] [Related]
28. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
[TBL] [Abstract][Full Text] [Related]
29. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Eagye KJ; Nicolau DP
J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
[TBL] [Abstract][Full Text] [Related]
30. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
He W; Kaniga K; Lynch AS; Flamm RK; Davies TA
Diagn Microbiol Infect Dis; 2012 Dec; 74(4):417-9. PubMed ID: 22995366
[TBL] [Abstract][Full Text] [Related]
31. Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
Beović B; Kreft S; Seme K; Cizman M
J Chemother; 2011 Aug; 23(4):216-20. PubMed ID: 21803699
[TBL] [Abstract][Full Text] [Related]
32. Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.
Tartof SY; Kuntz JL; Chen LH; Wei R; Puzniak L; Tian Y; Im TM; Takhar HS; Merchant S; Lodise T
JAMA Netw Open; 2018 Oct; 1(6):e183927. PubMed ID: 30646267
[TBL] [Abstract][Full Text] [Related]
33. Carbapenem resistance mechanism and risk factors of Pseudomonas aeruginosa clinical isolates from a University Hospital in Xi'an, China.
Zhang JF; Chen BL; Xin XY; Zhao HB; Wang HY; Song H; Xu ZK
Microb Drug Resist; 2009 Mar; 15(1):41-5. PubMed ID: 19226194
[TBL] [Abstract][Full Text] [Related]
34. Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains.
Tsai MH; Wu TL; Su LH; Lo WL; Chen CL; Liang YH; Chiu CH
Int J Antimicrob Agents; 2014 Dec; 44(6):541-5. PubMed ID: 25264129
[TBL] [Abstract][Full Text] [Related]
35. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
[No Abstract] [Full Text] [Related]
37. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
[TBL] [Abstract][Full Text] [Related]
38. A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa.
Wangchinda W; Kaye KS; Patel TS; Albin OR; Saravolatz L; Petrie JG; Pogue JM
J Antimicrob Chemother; 2024 Jun; 79(6):1337-1345. PubMed ID: 38581308
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
40. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates.
Pires dos Santos R; Jacoby T; Pires Machado D; Lisboa T; Gastal SL; Nagel FM; Kuplich NM; Konkewicz L; Gorniak Lovatto C; Pires MR; Goldani LZ
Infect Control Hosp Epidemiol; 2011 Jun; 32(6):584-90. PubMed ID: 21558771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
